Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Gordon Research Conference on Glia Biology: Functional Interactions among Glia & Neurons
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
[Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation.]
Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Inflammatory cortical demyelination in early multiple sclerosis.
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting
Inflammation-induced fatigue: Exploring neurobiological mechanisms and potential treatments
FDA approval announcement for ofatumumab
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.

Pages